About CannaLean

About company

CannaLean is an R&D company developing CBD based solutions to benefit millions of patients suffering from Dyslipidemia. The company is committed to the research and development of a novel proprietary formulation of Cannabidiol (CBD) and Chitosan that will potentially benefit millions of patients suffering from Dyslipidemia. CannaLean's preliminary results show the effect of the formulation of cholesterol and triglyceride reduction. It uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. CannaLean was founded in 2017 and is headquartered in Bene Beraq, Israel.